Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (9555)	11/23/2003 9:39:12 PM
From: fred hayes	Read Replies (1) \| Respond to of 52153

Speaking of Garren, he is recommending Praecis on the basis of expected approval of what used to be called Abarelix. It was partnered with Amgen and Sanofi, and both dropped the deal after initial FDA concerns. Praecis seemed to signal that the problems were minor, could be addressed by another straight-forward study, completed the study, resubmitted the application, and should hear a decision next week. I just don't get it. Why would Amgen and Sanofi walk away from this drug if approval were going to be so easy? The data showed no survival benefit for Abarelix. There must be something going on here I don't understand. Any insights would be appreciated... fred hayes